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Tryptic digests of fragment AZ99_585 of penicilloylated serum albumin obtained from two penicillin-treated patients or prepared by in vitro conjuga- 
tion, were analyzed by a tandem immunoatlinity reversed-phase HLPC. Determinations of benzyl penicilloyl groups (BPO) were performed on 
the different fractions. Three BP0 containing peptides were identified by their amino acid sequence and the bound BP0 were located on lysines 
432, 541 and 545. Six major BP0 binding sites were thus identified on the whole albumin molecule. All of them are lysine residues and correspond 
to a limited number of definite structures in which lysine and serine residues appear to be closely associated. 
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1. INTRODUCTION 
Benzyl penicilloyl groups (BPO) result from the 
cleavage of the,&lactam ring of penicillin G. They form 
covalent binding between their carbonyl group and E- 
amino groups of albumin molecules. They thus give rise 
to penicilloyl/albumin conjugates which have lost all 
antibacterial activity but possess an immunogenic 
potential; BP0 are thus considered to be the major an- 
tigenic determinant in penicillin allergy [l-3]. 
In patients treated with large amounts of penicillin, 
a transient bisalbuminemia was observed [4] and it has 
been demonstrated that the covalent fixation of BP0 
was responsible for the presence of the fast elec- 
trophoretic band of albumin [5]. Recently three BPO- 
binding sites have been located on the fragment 
Ci24-298 of albumin, on lysines 190, 195 and 199 [6]. 
The purpose of this work was firstly to identify the 
other BPO-binding sites on the albumin molecule, and 
secondly to determine if similar sequences are involved 
in these fixations, in order to confirm the possible 
mechanism of penicilloylation suggested by the 
previous results. 
2. MATERIALS AND METHODS. 
2.1. Reagents and penicilloylated albumins 
For high-performance liquid chromatography (HPLC), all the 
chemicals used were of HPLC grade. 
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For amino acid analysis as for recurring Edman degradation, the 
chemicals used were of sequanal grade, the other reagents were of 
analytical grade. 
Control HSA was obtained from Centre National de Transfusion 
Sanguine. Free fatty acids were removed according to Chen [7]. 
Sera were obtained from two patients in the Institut Pasteur 
Hospital, who received intravenously 50 x lo6 IU penicillin G per 
day during 3-4 weeks and the fast serum albumin was separated from 
each serum by ion exchange chromatography on DEAE Sephadex 
15,81. 
A BPO-human serum albumin (BPO-HSA) conjugate was 
prepared in vitro as previously described [8]. 
2.2. Preparation, reduction and carboxymethylation of the CNBr 
Control and penicilloylated fragments A were prepared from con- 
trol HSA and from patients’ fast serum albumin fractions or from in 
vitro BPO/HSA conjugate as described; i.e. CNBr digestion follow- 
ed by an HPLC separation of fragments A, B and C [6]. 
Denaturation, disulfide cleavage and alkylation were performed as 
described by Swenson et al. [9]: the A containing fractions were dried 
and dissolved in 1 M Tris-HCl buffer, pH 8.0, containing 6 M urea 
and a IO-fold molar excess of dithiothreitol over the -SH concentra- 
tion and kept overnight at 40°C under nitrogen. Iodoacetic acid in 
1 N NaOH (1.3.fold molar excess over total thiols) was added and the 
mixture was maintained in the dark for 4 h, before the reaction was 
stopped by addition of fl-mercaptoethanol. 
2.3. Obtainment and tryptic digestion of thefourpeptides A, 117-519, 
AI 330-446, & 299-329, A4 ~9-~5 
The mixture obtained after reduction was loaded onto an 
Aquapore RP-300 column equilibrated in trifluoroacetic acid (TFA) 
0.05% and the peptides were eluted with a 30 min linear gradient 
from 0% to 100% of acetonitrile/2-propanol/water 2: 1 : 2, v/v, 
0.05% TFA at a flow rate of 1 ml/min. The HPLC fractions col- 
lected every 30 s were evaporated to dryness and BP0 was detected 
by Enzyme Immuno Assay (EIA) as previously described [6]. 
Tryptic digestion was performed on penicilloylated fragments Ai 
and AZ in 0.1 M phosphate buffer, pH 7.8, overnight at room 
temperature using TPCK-trypsin (Sigma) (molar ratio E/S = l/50). 
The enzymatic reaction was stopped by 10 min heating at 100°C. 
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2.4. Isolation and separation of the penicilloylated fragments from 
AI and A2 tryptic digests 
2.4.1. Preparation of immunoaffinity column by covalent immo- 
bilization 
13 mg of affinity pure rabbit anti-BP0 antibodies obtained from 
the immune sera already prepared [lo] were dissolved in 18 ml of 1 M 
phosphate buffer, pH 7, and recycled through an Ultraffinity-EP col- 
umn (5 cm x 4.6 mm i.d., Beckman) overnight at a 0.2 ml/min flow 
rate. 8 mg of IgG were thus immobilized. The column was washed in 
1 M phosphate buffer, pH 7, and stored in the same buffer. It was 
equilibrated with 10 mM phosphate buffer, pH 7, 0.15 M NaCl 
(PBS) before use. 
2.4.2. Apparatus 
The immunoaffinity column was connected to a reversed-phase 
column (Nucleosil 5C1s, 25 cm x 4.6 mm i.d., SociCtt FranCaise 
Chromato Colonne) via a 6-way valve (Rheodyne) as described by 
Rybacek et al. Ill]. The switching valve contained the affinity col- 
umn in place of a sample loop. The position of the switching valve 
determined whether the immunoaffinity and analytical columns were 
used in series or separately. 
2.4.3. Obtainment and separation of the penicilloylated fragments 
The tryptic digests of peptides A1 and A2 were loaded onto the af- 
finity column in PBS at a flow rate of 1 ml/min. The column was 
then washed with lo-15 ml of PBS at the same flow rate. Non- 
retained peptides were collected to check the absence of BPO. The 
valve was then switched to place both columns in line. The bound an- 
tigens were desorbed from the immunoaffinity column into the 
analytical column with a 0.1% TFA solution at a flow rate of 
I ml/min. After 10 min, the valve was switched, placing the im- 
munoaffinity column off-line to permit the analysis of the antigens 
by gradient elution on the analytical column. The reversed phase 
chromatographic separations were performed with a 30 min linear 
gradient from 0% to 100% of acetonitrile/isopropanol/water 
(2: 1:2, v/v), and 0.1% TFA at a flow rate of 1 ml/min. All runs 
were performed at room temperature and peptides were detected at 
220 nm. Fractions were collected every 0.25 min and analyzed for 
BP0 concentration. Simultaneously, the affinity column was re- 
equilibrated with loading buffer. 
2.5. Identification of peptides and location of the BP0 binding sites 
Amino acid analyses were performed with a Biotronik LC 5000 
analyzer after acid hydrolysis (5.7 N HCl, in vacua, llO”C, 24 h). 
On each penicilloylated fraction obtained the amino acid sequenc- 
ing was achieved using a 477 sequenator connected to a 120A PTH 
HPLC analyzer (Applied Biosystems). Moreover, a recurring Edman 
degradation using Tarr’s procedure [12] was performed on each pep- 
tide and the EIA for BP0 detection was realized at each cycle on the 
phenylthiohydantoin (PTH) derivative. 
The C-terminal amino acids were identified by amino acid analysis 
after reaction with carboxypeptidase A (Boehringer). 
3. RESULTS 
3.1. Obtainment and identification of the 
penicilloylated fragment A from the CNBr digests 
of the albumins 
Two penicilloyl containing peaks were observed from 
the CNBr digests of each of the 3 penicilloylated 
albumins, i.e. the two fast albumin fractions isolated 
from patients’ sera and the BPO/HSA conjugate 
prepared in vitro. The first one eluted at a retention 
time (RT) of 8.9 min was previously identified with 
238 
fragment cl246298 [6], the second one (RT: 12 min) was 
identified with fragment A299-585 by its amino acid 
analysis and by the determination of the C-terminal 
and N-terminal amino acids. No BP0 group was 
detected in the fragment Bl-123 of the different 
penicilloylated albumins. 
3.2. Separation of peptides from fragment A 
Fragment A299-585 COnSiStS of 4 chains held together 
by S-S bonds. Actually 4 peptides were obtained after 
reduction, S-carboxymethylation and HPLC separa- 
tion. The HPLC patterns of the reduced fragments A 
obtained from in vivo and in vitro penicilloylated 
albumins were identical. For each fragment A, two 
penicilloyl containing peaks were obtained, i.e. A1 and 
AZ at retention times of 20.8 and 23.2 min, respectively 
(Fig. 1). The peptides eluted in these fractions were 
identified with sequence 441-547 for A1 and 330-446 
for A2 by their amino acid analysis and by the deter- 
mination of the C- and N-terminal amino acids. 
3.3. Obtaining of the penicilloylated fragments from 
tryptic digests of peptides Al and AI 
lsolation and separation of penicilloylated fragments 
from A1 and AZ tryptic digests were achieved using the 
above-described ual-column chromatographic system. 
The HPLC patterns of the 3 tryptic digests of peptides 
A1 obtained from the two in vivo BPO/HSA and the 
in vitro conjugate were quite similar. Fig. 2 shows 
those obtained with one of the in vivo conjugates. In 
the 3 cases, two BPO-containing peaks were collected, 
i.e. Pep 19A1 (RT = 19.3 min) and Pep 21A1 (RT = 
21.4 min). The retention times of the two peaks observ- 
ed with the different digests of peptides A1 obtained 
from the 3 penicilloylated albumin samples were iden- 
tical but their respective height may vary from one sam- 
ple to another. In the same way, the patterns of the 3 
tryptic digests of peptides A2 were similar. Fig. 3 shows 
one obtained from an in vivo BPO/HSA. Two BPO- 
containing peaks were obtained i.e. Pep 20A2 (RT = 
20.1 min) and Pep 21A2 (RT = 21.2 min). A few other 
peaks were detected at 220 nm in all the digests, but 
they did not contain BPO. These peptides may have 
been non-specifically bound to the affinity column. 
Furthermore, non-retained peptides on the affinity col- 
umn were collected for BP0 detection: no 
penicilloylated peptides were detected. 
3.4. Identification of penicilloylated fragments and 
location of BPO-binding sites 
Each of the penicilloylated fragments isolated from 
the in vivo and in vitro penicilloylated albumins was 
analyzed for its amino acid sequence. In order to con- 
firm the BPO-binding site, BP0 determinations were 
done again at each cycle of the Edman degradation. 
The same results were obtained whatever the origin 
of the peptides. 
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Fig. 1. HPLC separation of the 4 peptidic chains from the CNBr Fig. 2. HPLC separation of the penicilloylated fragments from the 
fragment A299-ss5 of the fast albumin fraction isolated from a tryptic digest of peptide Al obtained from the same in vivo 
patient’ serum. (-) Peptide determination at 220 nm; (- - -) EIA conjugate. (-) Peptide determination at 220 nm; (iIw#I[B) EIA 
determination of BP0 on the corresponding fractions. determination of BP0 on the corresponding fractions. 
3.4.1. Fragments from peptide A1 
Pep 19A1: Ala-Thr- - Glu - Gln - Leu - Lys 
--L--L\ 
This sequence corresponds to that of fragment 
539-545 of the human serum albumin. No amino acid 
could be identified in the third cycle of the sequencing 
while BP0 was found in this fraction proving that bin- 
ding of BP0 occurs on lysine-541. 
Pep 21A1: Glu - Gln - Leu - - Ala - Val 
_A\--- 
This peptide was identified with sequence 542-548 of 
HSA, although the last PTH amino acid could not be 
identified. In fact, since this peptide came from a CNBr 
cleavage, the methionine-548 has been changed into 
homoserine or homoserine-lactone which cannot be 
identified as PTH derivatives. 
The fourth cycle of the sequencing corresponding to 
lysine-545 gave no PTH-derivative and was shown to be 
the BPO-binding site of this peptide since most of the 
BP0 was detected at this cycle. 
3.4.2. Fragments from peptide AZ 
Pep 21A2: Asn - Leu - Gly - - Val - Gly - Ser - Lys 
-------- 
Absorbance (DO) BP0 concentration (ng/ml) 
21.4 , 
Absorbance (DO) o.03 , BP0 concentration (ng/ml), 
300 
18 20 22 
Retention time (min.) 
24 
Fig. 3. HPLC separation of the penicilloylated fragments from the 
tryptic digest of peptide AZ obtained from the same in viva 
conjugate. (-) Peptide determination at 220 nm; (~l[I~RiIll) EIA
determination of BP0 on the corresponding fractions. 
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The sequencing pattern shows that Pep 21A2 cor- 
responds to sequence 429-436, BP0 being fixed on 
lysine-432 since no PTH derivative could be identified 
in the Edman cycle corresponding to this residue and 
BP0 was detected in the same fraction. 
Pep 20A2: Asn - Leu - Gly - - Val - Gly - Ser - Lys 
--__L-L-L- 
and Ala - Thr - - Glu - Gln - Leu - Lys 
_-_\--_ 
This fraction consisted of a mixture of two peptides 
corresponding to Pep 21A2 and Pep 19Ai. A partial 
separation of these two linked peptides was obtained by 
reversed-phase HPLC in acidic conditions. After elu- 
tion with acetonitrile, 0.1% TFA, only 20% of the mix- 
ture could be dissociated. Successive HPLC was 
necessary to achieve the separation of the two peptides. 
It has to be mentioned that the whole procedure was 
performed on a blank HSA sample and on blank lysine 
phenylthiohydantoin derivatives. No false positive 
result occurred at any step of the analysis. 
4. DISCUSSION 
The penicilloylated tryptic peptides of albumin frag- 
ment A were isolated using a tandem immunoaffinity 
and reversed-phase HPLC. This method permitted one 
to obtain the purified penicilloylated peptides by a 
single step procedure. Three binding sites for 
penicilloyl residue were unequivocally established: 
Lys-432, Lys-541, Lys-545. They account for approx- 
imately 75% of the total BP0 present on the albumin 
fragment A. 
It is worth noting that the same sites have been iden- 
tified for the two in vivo and for the in vitro 
penicilloylated albumins. 
The 3 binding sites identified on fragment A must be 
added to the 3 others, already identified on fragment C 
[S]. BP0 binding sites thus appear to be located on 
lysine residues. Moreover, only 6 different lysine 
residues out of a total of 59 can be penicilloylated. This 
result is in agreement with the theoretical model of 
Ahlstedt et al. [14]. In conditions of penicillin dosages 
similar to those of the present study, these authors 
calculate that a maximum of 6 different binding sites 
can be expected on the same albumin molecule. 
As previously observed for the 3 binding sites located 
on fragment C, Lys-432 is located near a serine from 
which it is separated by two amino acids, this position 
represents in an a-helix structure Lys and Ser residues 
as being the nearest. This supports the hypothetical 
mechanism of penicilloylation proposed by Yamana et 
al. [14]: an intermediate ester of penicilloic acid is likely 
to be formed with a hydroxyl group of a serine residue. 
This unstable ester could then undergo an acyl transfer 
to the primary amino group of a lysine residue in a 
suitable steric position. In contrast, for Lys-541 and 
Lys-545 there is no evidence for proximity to hydrox- 
ylated residues in the sequence. However, another 
serine residue could be suitably located in the tertiary 
structure of the albumin molecule or in the environ- 
ment of other HSA molecules. This hypothesis is sup- 
ported by the obtaining of Pep 20A2. This fragment 
consists of two peptides: Pep 19Ai and Pep 21A2 held 
together by strong interactions, since they are only par- 
tially broken under acidic dissociating conditions. This 
could suggest that these two sequences are closely 
located. So, Ser-435 could also participate in 
penicilloylation of Lys-541 or of Lys-545. 
BP0 binding sites thus seem to correspond to a 
limited number of definite structures. Two other lysine 
residues, namely Lys-205 and Lys-276, are located in 
similar respective positions from serine residues. 
However, they do not appear to be penicilloylated. It 
should be noted that for Lys-205, Ser-202, which would 
be associated with its penicilloylation, is already in- 
volved in penicilloylation of Lys-199. Concerning the 
second lysine, one can suppose it to be located in a part 
of the albumin molecule which would not be in the LY- 
helix structure. 
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